Member access

4-Traders Homepage  >  Shares  >  Xetra (Allemagne)  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG

 (MOR)
9
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra (Allemagne)
05/15/2013 05/16/2013 05/17/2013 05/20/2013 05/21/2013 Date
35.115(c) 35.92(c) 35.76(c) 35.25(c) 35.82(c) Last
65 024 132 673 66 725 33 431 60 505 Volume
-0.30% +2.29% -0.45% -1.43% +1.62% Change
More quotes
Company
MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004.

 
Read more
Sector
Biotechnology
Calendar
05/22 | 11:00amPresentation
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2013 58,6 M
EBIT 2013 -17,2 M
Net income 2013 -7,91 M
Finance 2013 132 M
Yield 2013 -
Sales 2014 64,9 M
EBIT 2014 -4,91 M
Net income 2014 -3,46 M
Finance 2014 127 M
Yield 2014 -
PER 2013 -
PER 2014
EV / Sales 2013 11,8x
EV / Sales 2014 10,7x
Capitalization 821 M
More Financials
Latest news on MORPHOSYS AG
05/13 MORPHOSYS AG: MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in..
05/13 MORPHOSYS AG: Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgk..
05/10 MORPHOSYS AG: MorphoSys Announces First Scientific Publication on Novel Antibod..
05/10 MORPHOSYS AG: Announces First Scientific Publication on Novel Antibody Platfor..
05/08 MORPHOSYS AG: to Present at Four Investor Conferences in May
05/03 MORPHOSYS AG: Reports Results for the First Quarter of 2013
05/02 MORPHOSYS AG: MorphoSys Announces Clinical Milestone in Ophthalmology Program
05/02 MORPHOSYS AG: Announces Clinical Milestone in Ophthalmology Program
04/29MORPHOSYS AG: quaterly earnings release
04/26 MORPHOSYS AG: MorphoSys to Host Q1 2013 Conference Call on May 3, 2013
04/26 MORPHOSYS AG: to Host Q1 2013 Conference Call on May 3, 2013
04/26 MORPHOSYS AG: Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Ac..
More news
Forum MORPHOSYS AG
Be the first to post a message on MORPHOSYS AG
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Copyright © 2013 Surperformance. All rights reserved.